

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 244

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣795佰萬元(NTD 795mn)

營業項目Business：

原料藥API (64.94%)

中間體Intermediate (24.39%)

特用化學品 Custom-made chemicals (10.67%)

公司概況 Outline

	2018.Q1	Y2017
歐洲Europe	46.37%	42.07%
美洲America	29.88%	21.29%
亞洲Asia	7.60%	21.37%
國內Taiwan	14.98%	14.21%
其他 others	1.17%	1.06%
合計Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:
生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:
製劑中之有效成分 Curative ingredient



下游
Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2018.Q1	2017Y
營收Sales	425,646	1,301,050
營業成本COGS	(293,909)	(906,694)
毛利Gross Profit	131,737	394,356
毛利率 GP Ratio	30.9%	30.3%
營業費用Operating Expenses	(51,117)	(161,307)
營業利益Operating Income	80,620	233,049
營業外損益Non-Operating In/Ex	(7,354)	1,725
稅前淨利 Net Profit before Tax	73,266	234,774
所得稅Income Tax		(43,798)
本期淨利Net Profit after Tax		190,976

產品組合-Products

Y2015	%		Y2016	%		Y2017	%
HOCLQ	21.52		HOCLQ	34.94		S-MMAA / Dulo	13.14
VA Series	18.21		PGA	12.73		VA Series	12.48
PGA	17.14		VA Series	13.55		HOCLQ	12.47
LPF.Na	7.48		Pent-2 / PEB.Na	6.70		LPF.Na	9.41
5-HMT / 5-wing	4.61		S-MMAA / Dulo	5.32		PGA	9.22
Pent-2 / PEB.Na	4.47		5-HMT / 5-wing	5.21		Pent-2 / PEB.Na	8.69
S20/38	4.01		LPF.Na	4.01		5-HMT / 5-wing	6.26
S-MMAA / Dulo	3.81						
Total	81.25		Total	82.46		Total	71.67

產品組合-Products

Product	%	2018 Q1 Sales (NT\$)
VA series	26.15	111,295,332
HOCLQ Sulfate	20.81	88,560,320
S-MMAA / Dulo	13.59	57,839,669
PGA	8.61	36,629,249
Pent-2 / PEB.Na	3.68	15,682,934


重點產品介紹 Product Profile

- Hydroxychloroquine Sulfate
- (S)-MMAA / Duloxetine HCl
- VA / DiVANa / NaVA
- Menthadienol & Olivetol
- Brinzolamide
- Benzhydrylamine / 3-Azetidinol
- Ritalinic acid / Methylphenidate
- d-Ritalinic acid / Dexmethylphenidate

Hydroxychloroquine sulfate

- 適應症 Application:


風濕性關節炎(rheumatoid arthritis)、瘧疾(malaria)、慢性多形性日光疹、慢性圓板狀紅斑症(discoid and systemic lupus erythematosus)



S-MMAA/Duloxetine HCl

- 適應症 Application:


重鬱症(major depressive disorder)、廣泛性焦慮症
(generalized anxiety disorder)、糖尿病週邊神經痛
(diabetic neuropathy)、纖維肌痛 (Fibromyalgia)、
慢性腰痛(日本地區) lower back pain (only in Japan)



VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate

- 適應症 Application :
癲癇(seizure)、躁鬱症(bipolar disorder)、
偏頭痛(migraine headaches)



Menthadienol, Olivetol (1)

1. Dronabinol 之關鍵中間體

Key intermediate of Dronabinol

● 適應症 Applications :

① 化療引起的噁心、嘔吐

Nausea and vomiting due to chemotherapy

② 愛滋病引起之厭食症 anorexia due to AIDS

Menthadienol, Olivetol (2)

2. Cannabidiol (CBD大麻二酚)之關鍵中間體

Key intermediate of CBD

- 適應症：好發於兒童的兩種罕見癲癇。
- 經第三方專家小組於 4/19 投票通過，支持批准 Epidiolex (GW 之大麻二酚新藥)，FDA將於6月決定。
- 此款藥物的批准，意味著將開啟大麻衍生藥物療法的新紀元。
- Application: for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients aged 2 years and older.
- A FDA committee on 4/19 recommended the approval of Epidiolex (new drug of GW); FDA will make final decision in June.
- The approval of Epidiolex will become a milestone for Cannabinoids derivatives.

Brinzolamide

- 適應症 Application：青光眼 (glaucoma)
- 單方：Brinzolamide
- 複方：Brinzolamide+Timolol
- 製劑需求量 (FDF consumption): ~2MT, US\$ 6.3億 (9/30/2016~9/30/2017)。

Benzhydrylamine / 3-Azetidinol

- 適應症 Application：降血壓 (hypertension)、新抗生素 (new antibiotics)、新阿茲海默症中間體 (intermediate used for new Alzheimer treatment)

Ritalinic acid / Methylphenidate (MEPH)

d-Ritalinic acid / Dexmethylphenidate (dex-MEPH)

- 適應症 Application :
注意力不足 (attention deficit hyperactivity disorder (ADHD)
、過動症 (narcolepsy)
- MEPH 製劑需求量 (FDF consumption):
38MT, US\$ 32.4億 (9/30/2016~9/30/2017) 。
- Dex-MEPH製劑需求量 (FDF consumption):
2.4MT, US\$ 7億 (9/30/2016~9/30/2017) 。

新市場 (New Market) :

與印度、中國及新興國家之合作

Partner with India, China and Emerging countries

新藥方向 (New drugs):

- 1) 中樞神經用藥 (CNS)
- 2) 失智症 (dementia)
- 3) 癌症用藥 (oncology)
- 4) 免疫療法 (immunotherapy)
- 5) 管制藥 (controlled substance)

GMP Status(GMP現況)

<i>API</i>	<i>CGMP Certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*) (#)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)(#)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011	2014			
Duloxetine Hydrochloride	2012	2014	2010/2011		2016
Thiopental	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013	2014	2014		
Hydroxychloroquine Sulfate(#)	2014		2014		2014
Clindamycin Palmitate HCl			2011		
Cyclophosphamide	2014		2012		
Brinzolamide	2015		2015		
Probuco	2015		2004		2015
Atomoxetine HCl	2016				

(*)(**) FDA inspection: Nov. 2005 / April 2012, (*) EDQM inspection: Nov. 2010, (#) FDA inspection: Dec. 2014.

簡報完畢



敬請指教